A Mouse Study Found Two-Way THC–Morphine Cross-Tolerance Under Specific Regimens

A mouse experiment found reduced THC antinociception after morphine exposure and reduced morphine responses after repeated THC. The evidence supports two-way cross-tolerance under the tested conditions, not a universal rule across all opioid–cannabinoid combinations.

The two directions used different pretreatments

Morphine tolerance was induced with an implanted pellet. Repeated injected THC was used for the reverse exposure history. Control groups received placebo pellets or vehicle. These are distinct regimens, so the two directions should not be described as identical exposures with merely switched labels.

The challenge outcomes defined the conclusion

THC produced less antinociception in morphine-tolerant animals than in controls. Morphine produced smaller antinociceptive and hypothermic effects in THC-tolerant mice. The abstract therefore provides a narrower endpoint account than an assertion that every effect of both drugs became cross-tolerant.

Cross-tolerance does not identify a shared receptor by itself

The authors proposed a possible interaction involving mu-opioid mechanisms. Reduced responsiveness after another drug's exposure does not alone prove that both compounds bind the same receptor or that one receptor mechanism explains the whole result. The supplied abstract is truncated, limiting further mechanistic detail.

The study is useful alongside experiments with one-way or absent cross-tolerance because the discrepancy directs attention to species, exposure and assay. It does not establish how an opioid-tolerant patient will respond to cannabis or justify a human dose conversion between THC and morphine.

Related: interpreting cannabis tolerance claims.

Research cited

Thorat SN; Bhargava HN. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. European journal of pharmacology (1994). doi:10.1016/0014-2999(94)90003-5. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

THC and CB1 Blockade Changed Fat Intake Differently Across Feeding Schedules in Female Rats

A female-rat feeding study found that THC increased fat intake in one access schedule while rimonabant reduced intake in another. The feeding history and experimental group mattered to the direction and persistence of the response. Limited access created different eating patterns Rats had unrestricted chow and water, with groups differing…

Spread the love

Read Article: THC and CB1 Blockade Changed Fat Intake Differently Across Feeding Schedules in Female Rats

mTOR Inhibition Prevented Some THC Memory Effects When Given Before Exposure, Not After Cessation

In a mouse THC study, mTOR inhibition prevented selected memory-related effects when given before exposure but did not prevent a residual cognitive deficit when introduced after chronic THC stopped. Timing changed the intervention's result. Acute effects separated by endpoint Temsirolimus prevented acute anxiety-like and amnesic-like effects. THC-related anxiolysis, hypothermia, reduced…

Spread the love

Read Article: mTOR Inhibition Prevented Some THC Memory Effects When Given Before Exposure, Not After Cessation

Partial MAGL Inhibition Preserved Repeated Pain-Response and Gastric Benefits in Mice

A mouse study found that repeated lower-dose JZL184 preserved antinociceptive and gastroprotective effects that became tolerant under higher-dose regimens. The result supports a dose-dependent experimental window, not a validated human treatment schedule. Two disease-related models were used Researchers examined neuropathic pain after sciatic nerve constriction and gastric hemorrhage induced by…

Spread the love

Read Article: Partial MAGL Inhibition Preserved Repeated Pain-Response and Gastric Benefits in Mice

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us